Here Are Some Essential Facts About United Therapeutics (UTHR)

Large-cap health care company United Therapeutics has moved -0.1% this overnight, reaching $239.98 per share. In contrast, the average analyst target price for the stock is $286.96.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is based in the United States.

What to Consider if You Are Thinking of Buying United Therapeutics:

  • United Therapeutics has moved -13.0% over the last year.

  • UTHR has a forward P/E ratio of 10.9 based on its EPS guidance of 21.97.

  • Over the last 6 years, earnings per share (EPS) have been growing at a compounded average rate of 5.2%.

  • The company has a price to earnings growth (PEG) ratio of 1.26.

  • Its Price to Book (P/B) ratio is 1.97

United Therapeutics Has Irregular Cash Flows

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 955,500 191,200 764,300 15.16
2022 802,500 138,800 663,700 39.02
2021 598,200 120,800 477,400 -31.45
2020 755,700 59,300 696,400 339.89
2019 -206,600 83,700 -290,300 -148.87
2018 778,400 184,400 594,000

United Therapeutics's free cash flows have a decent average of $484.25 Million over the last 6 years, but they are highly variable since their coefficient of variability is 508.5%. The compounded average growth rate over this period is 4.3%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.